Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers

Christopher S. Hollenbeak, Afif N. Kulaylat, Heath Mackley, Wayne Koch, Eric W. Schaefer, David Goldenberg

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

IMPORTANCE In the United States, nearly 8400 patients die each year from oral cavity and pharynx cancers, most of whom are 65 years and older; however, the costs attributable to these cancers are not well described. OBJECTIVE To identify the primary determinants of cost in patients with oral and pharyngeal cancer. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort analysis of data from Medicare and Surveillance, Epidemiology, and End Results hospitals (January 1, 1995, through December 31, 2005), we studied patients 66 years and older with newly diagnosed oral cavity (n = 6724) and pharyngeal (n = 3987) cancers. MAIN OUTCOMES AND MEASURES Five-year cumulative costs, defined as Medicare Parts A and B payments, were estimated using inverse probability weighting. Linear regression analysis with inverse probability weighting was used in multivariate analyses of costs to estimate the effects of covariates on cumulative costs. RESULTS In multivariate analyses, costs were significantly increased by demographics, comorbidities, and treatment selection. Compared with white patients, African Americans accumulated $11 450 (95%CI, $1320-$22 299) and $25 093 (95%CI, $14 917-$34 985) more in costs for oral cavity and pharyngeal cancers, respectively. The presence of 1 or 2 comorbidities increased the mean 5-year cumulative costs by $13 342 (95%CI, $6248-$19 186) and $14 139 (95%CI, $6009-$22 217) for patients with oral cavity and pharyngeal cancers, respectively. For 3 or more comorbidities, the mean 5-year cumulative costs increased by $22 196 (95%CI, $15 319-$28 614) and $27 799 (95%CI, $19 139-$36 702) for patients with oral cavity and pharyngeal cancers, respectively. Patients who received chemotherapy accumulated a mean of $26 919 (95%CI, $18 309-$35 056) and $37 407 (95%CI, $29 971-$44 644) more in costs by 5 years for oral cavity and pharyngeal cancers, respectively. CONCLUSIONS AND RELEVANCE Oral and pharyngeal cancer is burdensome to elderly patients from a Medicare cost perspective. Several factors were associated with 5-year costs, including some modifiable factors that may be potential targets for interventions to reduce overall costs.

Original languageEnglish (US)
Pages (from-to)628-635
Number of pages8
JournalJAMA Otolaryngology - Head and Neck Surgery
Volume141
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Pharyngeal Neoplasms
Mouth Neoplasms
Medicare
Mouth
Costs and Cost Analysis
Comorbidity
Medicare Part A
Medicare Part B
Multivariate Analysis
Enoxacin
Pharynx

All Science Journal Classification (ASJC) codes

  • Surgery
  • Otorhinolaryngology

Cite this

@article{e3975271273147a5bc57a4302f4a0b4f,
title = "Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers",
abstract = "IMPORTANCE In the United States, nearly 8400 patients die each year from oral cavity and pharynx cancers, most of whom are 65 years and older; however, the costs attributable to these cancers are not well described. OBJECTIVE To identify the primary determinants of cost in patients with oral and pharyngeal cancer. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort analysis of data from Medicare and Surveillance, Epidemiology, and End Results hospitals (January 1, 1995, through December 31, 2005), we studied patients 66 years and older with newly diagnosed oral cavity (n = 6724) and pharyngeal (n = 3987) cancers. MAIN OUTCOMES AND MEASURES Five-year cumulative costs, defined as Medicare Parts A and B payments, were estimated using inverse probability weighting. Linear regression analysis with inverse probability weighting was used in multivariate analyses of costs to estimate the effects of covariates on cumulative costs. RESULTS In multivariate analyses, costs were significantly increased by demographics, comorbidities, and treatment selection. Compared with white patients, African Americans accumulated $11 450 (95{\%}CI, $1320-$22 299) and $25 093 (95{\%}CI, $14 917-$34 985) more in costs for oral cavity and pharyngeal cancers, respectively. The presence of 1 or 2 comorbidities increased the mean 5-year cumulative costs by $13 342 (95{\%}CI, $6248-$19 186) and $14 139 (95{\%}CI, $6009-$22 217) for patients with oral cavity and pharyngeal cancers, respectively. For 3 or more comorbidities, the mean 5-year cumulative costs increased by $22 196 (95{\%}CI, $15 319-$28 614) and $27 799 (95{\%}CI, $19 139-$36 702) for patients with oral cavity and pharyngeal cancers, respectively. Patients who received chemotherapy accumulated a mean of $26 919 (95{\%}CI, $18 309-$35 056) and $37 407 (95{\%}CI, $29 971-$44 644) more in costs by 5 years for oral cavity and pharyngeal cancers, respectively. CONCLUSIONS AND RELEVANCE Oral and pharyngeal cancer is burdensome to elderly patients from a Medicare cost perspective. Several factors were associated with 5-year costs, including some modifiable factors that may be potential targets for interventions to reduce overall costs.",
author = "Hollenbeak, {Christopher S.} and Kulaylat, {Afif N.} and Heath Mackley and Wayne Koch and Schaefer, {Eric W.} and David Goldenberg",
year = "2015",
month = "7",
day = "1",
doi = "10.1001/jamaoto.2015.0940",
language = "English (US)",
volume = "141",
pages = "628--635",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "7",

}

Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers. / Hollenbeak, Christopher S.; Kulaylat, Afif N.; Mackley, Heath; Koch, Wayne; Schaefer, Eric W.; Goldenberg, David.

In: JAMA Otolaryngology - Head and Neck Surgery, Vol. 141, No. 7, 01.07.2015, p. 628-635.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Determinants of medicare costs for elderly patients with oral cavity and pharyngeal cancers

AU - Hollenbeak, Christopher S.

AU - Kulaylat, Afif N.

AU - Mackley, Heath

AU - Koch, Wayne

AU - Schaefer, Eric W.

AU - Goldenberg, David

PY - 2015/7/1

Y1 - 2015/7/1

N2 - IMPORTANCE In the United States, nearly 8400 patients die each year from oral cavity and pharynx cancers, most of whom are 65 years and older; however, the costs attributable to these cancers are not well described. OBJECTIVE To identify the primary determinants of cost in patients with oral and pharyngeal cancer. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort analysis of data from Medicare and Surveillance, Epidemiology, and End Results hospitals (January 1, 1995, through December 31, 2005), we studied patients 66 years and older with newly diagnosed oral cavity (n = 6724) and pharyngeal (n = 3987) cancers. MAIN OUTCOMES AND MEASURES Five-year cumulative costs, defined as Medicare Parts A and B payments, were estimated using inverse probability weighting. Linear regression analysis with inverse probability weighting was used in multivariate analyses of costs to estimate the effects of covariates on cumulative costs. RESULTS In multivariate analyses, costs were significantly increased by demographics, comorbidities, and treatment selection. Compared with white patients, African Americans accumulated $11 450 (95%CI, $1320-$22 299) and $25 093 (95%CI, $14 917-$34 985) more in costs for oral cavity and pharyngeal cancers, respectively. The presence of 1 or 2 comorbidities increased the mean 5-year cumulative costs by $13 342 (95%CI, $6248-$19 186) and $14 139 (95%CI, $6009-$22 217) for patients with oral cavity and pharyngeal cancers, respectively. For 3 or more comorbidities, the mean 5-year cumulative costs increased by $22 196 (95%CI, $15 319-$28 614) and $27 799 (95%CI, $19 139-$36 702) for patients with oral cavity and pharyngeal cancers, respectively. Patients who received chemotherapy accumulated a mean of $26 919 (95%CI, $18 309-$35 056) and $37 407 (95%CI, $29 971-$44 644) more in costs by 5 years for oral cavity and pharyngeal cancers, respectively. CONCLUSIONS AND RELEVANCE Oral and pharyngeal cancer is burdensome to elderly patients from a Medicare cost perspective. Several factors were associated with 5-year costs, including some modifiable factors that may be potential targets for interventions to reduce overall costs.

AB - IMPORTANCE In the United States, nearly 8400 patients die each year from oral cavity and pharynx cancers, most of whom are 65 years and older; however, the costs attributable to these cancers are not well described. OBJECTIVE To identify the primary determinants of cost in patients with oral and pharyngeal cancer. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort analysis of data from Medicare and Surveillance, Epidemiology, and End Results hospitals (January 1, 1995, through December 31, 2005), we studied patients 66 years and older with newly diagnosed oral cavity (n = 6724) and pharyngeal (n = 3987) cancers. MAIN OUTCOMES AND MEASURES Five-year cumulative costs, defined as Medicare Parts A and B payments, were estimated using inverse probability weighting. Linear regression analysis with inverse probability weighting was used in multivariate analyses of costs to estimate the effects of covariates on cumulative costs. RESULTS In multivariate analyses, costs were significantly increased by demographics, comorbidities, and treatment selection. Compared with white patients, African Americans accumulated $11 450 (95%CI, $1320-$22 299) and $25 093 (95%CI, $14 917-$34 985) more in costs for oral cavity and pharyngeal cancers, respectively. The presence of 1 or 2 comorbidities increased the mean 5-year cumulative costs by $13 342 (95%CI, $6248-$19 186) and $14 139 (95%CI, $6009-$22 217) for patients with oral cavity and pharyngeal cancers, respectively. For 3 or more comorbidities, the mean 5-year cumulative costs increased by $22 196 (95%CI, $15 319-$28 614) and $27 799 (95%CI, $19 139-$36 702) for patients with oral cavity and pharyngeal cancers, respectively. Patients who received chemotherapy accumulated a mean of $26 919 (95%CI, $18 309-$35 056) and $37 407 (95%CI, $29 971-$44 644) more in costs by 5 years for oral cavity and pharyngeal cancers, respectively. CONCLUSIONS AND RELEVANCE Oral and pharyngeal cancer is burdensome to elderly patients from a Medicare cost perspective. Several factors were associated with 5-year costs, including some modifiable factors that may be potential targets for interventions to reduce overall costs.

UR - http://www.scopus.com/inward/record.url?scp=84937896213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937896213&partnerID=8YFLogxK

U2 - 10.1001/jamaoto.2015.0940

DO - 10.1001/jamaoto.2015.0940

M3 - Article

C2 - 26042925

AN - SCOPUS:84937896213

VL - 141

SP - 628

EP - 635

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 7

ER -